Abstract
Keap1 binds to the Nrf2 transcription factor to promote its degradation, resulting in the loss of gene products that protect against oxidative stress. While cell-active small molecules have been identified that modify cysteines in Keap1 and effect the Nrf2 dependent pathway, few act through a non-covalent mechanism. We have identified and characterized several small molecule compounds that specifically bind to the Keap1 Kelch-DC domain as measured by NMR, native mass spectrometry and X-ray crystallography. One compound upregulates Nrf2 response genes measured by a luciferase cell reporter assay. The non-covalent inhibition strategy presents a reasonable course of action to avoid toxic side-effects due to non-specific cysteine modification.
Copyright © 2013 Elsevier Ltd. All rights reserved.
MeSH terms
-
Carrier Proteins
-
Crystallography, X-Ray
-
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
-
Intracellular Signaling Peptides and Proteins / chemistry
-
Intracellular Signaling Peptides and Proteins / metabolism*
-
Kelch-Like ECH-Associated Protein 1
-
NF-E2-Related Factor 2 / antagonists & inhibitors*
-
NF-E2-Related Factor 2 / chemistry
-
NF-E2-Related Factor 2 / metabolism*
-
Protein Binding / drug effects
-
Protein Structure, Tertiary
-
Small Molecule Libraries / pharmacology*
-
Spectrometry, Mass, Electrospray Ionization
-
Structure-Activity Relationship
-
Thermodynamics
Substances
-
Carrier Proteins
-
Intracellular Signaling Peptides and Proteins
-
KEAP1 protein, human
-
KLHDC1 protein, human
-
Kelch-Like ECH-Associated Protein 1
-
NF-E2-Related Factor 2
-
Small Molecule Libraries